On February 11, a significant advancement in the healthcare technology sector was marked by the integration of the "Infectious Disease Smart System" developed by Shengxiang Biotech with the DeepSeek-R1 model. This local deployment is set to enhance the capabilities of digital intelligence systems, particularly in data retrieval and mining processes, thereby increasing the efficiency with which infectious diseases are managed. As the integration progresses, it is expected that the smart infectious disease system, leveraging big data analytics and advanced predictive technologies, will enable the forecasting of respiratory pathogen trends for the upcoming two weeks. This is anticipated to substantially improve the strategies for infectious disease prevention and control.

With the incorporation of DeepSeek into their smart system, Shengxiang Biotech is poised to initiate the establishment of a specialized product knowledge base. This database is conceived as the "intelligent brain" encompassing extensive information on various infectious disease testing products developed by the company. By utilizing DeepSeek's superior search and correlation capabilities, the knowledge base aims to provide the research and development teams with profound technical indexing and references, thus supporting product development and scientific studies. Furthermore, it promises to enhance customer service by delivering professional, comprehensive, and timely consulting regarding their products, thereby strengthening their competitive position in the marketplace.

The DeepSeek tool is renowned for its exceptional language comprehension and robust information retrieval capabilities. Following its integration into the infectious disease smart system, it is expected to meticulously sift through enormous volumes of medical testing data, extracting critical information about infectious disease pathogens, cutting-edge research results, clinical case studies, and the latest authoritative treatment guidelines. This data will significantly assist AI-driven diagnostic systems in evolving their medical knowledge autonomously, which is crucial for accurate diagnosis and treatment approaches.

In terms of practical applications, Shengxiang Biotech intends to leverage the synergy between DeepSeek's deep learning approaches and their proprietary product knowledge base. They aim to achieve a high level of integration with the infectious disease smart system along with existing cooperative hospital detection data and treatment pathways. This collaboration will focus on continuously optimizing training related to diagnoses and treatments of respiratory infectious diseases. The overarching goal is to elevate the intelligent healthcare service model that primarily involves hospitals, includes community engagement, and emphasizes at-home care.

At the forefront, primary care clinicians will benefit from enhanced early diagnostics, promoting greater accuracy in diagnosis and decision-making efficiency. For home consumers, there will be intelligent reminders for appropriate antibiotic use based on supportive data provided by the system. In the realm of disease prevention and control, the smart infectious disease system will merge big data analysis with predictive technologies to forecast respiratory pathogen trends effectively within a two-week outlook. This insight will serve as a scientific basis for public health decision-making, thereby elevating the overall standard of infectious disease management.

On the product development front, Shengxiang Biotech plans to employ the open-source capabilities of the DeepSeek language model within laboratory testing workflows, resulting in the creation of AI-driven laboratory agents.

The benefits of this AI agent are substantial; it enables intelligent control over laboratory equipment as well as automated analysis of experimental data. For instance, in processing experimental results, the smart lab agent can swiftly analyze a large volume of test data. When evaluating nucleic acid testing data, the agent can accurately determine whether samples are infected with specific infectious pathogens, identifying both the type and subtype of these pathogens. Moreover, it will facilitate the automation of data classification, statistical processing, and learning.

Over the past year, against the backdrop of the burgeoning digital healthcare wave, Shengxiang Biotech has been actively investing in enhancing its technological capabilities in the realm of digital intelligence. Noteworthy collaborations, such as the partnership with IQVIA, highlight significant breakthroughs, especially in developing predictive models from vast healthcare datasets. Together, they successfully forecasted a potential surge in influenza cases by mid-December 2024, thereby gaining crucial time for public health interventions, and showcasing the transformative potential of digital technologies in managing infectious diseases.

Shengxiang Biotech has declared 2023 as a pivotal year in its AI-driven initiatives in the field of respiratory diseases. Plans for the "Shengxiang Respiratory AI Ecosystem Partner Conference" will see invitations extended to various intelligent digital partners, where new AI products will be officially announced, and ongoing improvements to the infectious disease smart system will be highlighted. The company's drive will focus on technological innovations that facilitate a shift in infectious disease diagnosis and treatment from traditional models to smart, precise approaches.

Currently, Shengxiang Biotech is earnestly working on the development of its computational power center to bolster efforts in the AI technology domain. This initiative will lay a robust foundation for the storage, processing, and analysis of vast healthcare data. Additionally, Shengxiang is concentrating on developing AI-driven models, aiming to uncover the intrinsic value embedded within healthcare data using machine learning and deep learning algorithms. The enhancement of functionalities within the infectious disease smart system will undoubtedly assist in clinical diagnoses and predictions concerning infectious diseases, ultimately enhancing the accuracy and scientific rigor of medical decision-making.

Recent research reports from Xiangcai Securities indicate that the intersection of AI and healthcare is garnering considerable interest within the market. AI applications are expanding across the pharmaceutical landscape, influencing not only diagnostics and treatment realms, but also surgical robotics, medical imaging technologies, drug design assistance, and genetic testing. As AI technologies continue to evolve and mature, it is expected that additional applications and fields may emerge, potentially leading to disruptive transformations within various industries.